Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Sandra Perez

Showing results (81-90 of 82) with videos related to

Pageof 9
Sort By:
You have reached the last page of results.This site can display upto 82 results.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|June 26, 2025
FOXC1 Expression Predicts Capecitabine Efficacy in Patients with Triple-Negative Breast Cancer from the GEICAM_CIBOMA TrialFederico Rojo, Clive R Taylor, Carlos Barrios, et al.
Blood Advances|July 16, 2025
TAFASITAMAB PLUS LENALIDOMIDE AS SALVAGE THERAPY IN DIFFUSE LARGE B-CELL LYMPHOMA: REAL-WORLD EXPERIENCE FROM GELTAMOAntonio Gutierrez, Izaskun Zeberio, Francisco Javier Penalvar, et al.
Pageof 9

Showing results (81-90 of 82) with videos related to

Sort By:
Pageof 9
You have reached the last page of results.This site can display upto 82 results.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|June 26, 2025
FOXC1 Expression Predicts Capecitabine Efficacy in Patients with Triple-Negative Breast Cancer from the GEICAM_CIBOMA TrialFederico Rojo, Clive R Taylor, Carlos Barrios, et al.
Blood Advances|July 16, 2025
TAFASITAMAB PLUS LENALIDOMIDE AS SALVAGE THERAPY IN DIFFUSE LARGE B-CELL LYMPHOMA: REAL-WORLD EXPERIENCE FROM GELTAMOAntonio Gutierrez, Izaskun Zeberio, Francisco Javier Penalvar, et al.
Pageof 9